Baseline characteristics of participants in phase II
| Characteristics | 18–50 years | 51–75 years | ||
| Placebo (N=40) | Intervention (N=160) | Placebo (N=16) | Intervention (N=64) | |
| Sex (N, %) | ||||
| Female | 15 (37.5) | 50 (31.2) | 7 (43.7) | 30 (46.9) |
| Male | 25 (62.5) | 110 (68.8) | 9 (56.3) | 34 (53.1) |
| Age (mean-SD) | 34.2 (8.7) | 35.6 (7.8) | 55.8 (3.0) | 58.6 (6.2) |
| Underlying conditions (N,%) | ||||
| Chronic hypertension | 1 (2.5) | 8 (5.0) | 1 (6.3) | 15 (23.4) |
| Diabetes mellitus | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (9.4) |
| Hyperlipidaemia | 0 (0.0) | 0 (0.0) | 3 (18.8) | 10 (15.6) |
| Hypothyroidism | 1 (2.5) | 7 (4.4) | 0 (0.0) | 9 (14.1) |
| Baseline vital signs (mean-SD) | ||||
| Body temperature (°C) | 36.6 (0.3) | 36.6 (0.3) | 36.7 (0.2) | 36.7 (0.2) |
| Respiratory rate (per minute) | 15.0 (0.8) | 15.0 (0.9) | 15.1 (0.7) | 15.0 (0.5) |
| Heart rate (beats per minute) | 82.3 (11.2) | 83.5 (8.3) | 78.8 (7.0) | 79.1 (9.8) |
| Systolic blood pressure (mm Hg) | 122.1 (8.8) | 122.1 (12.2) | 122.9 (11.0) | 126.7 (9.1) |
| Diastolic blood pressure (mm Hg) | 79.2 (7.7) | 79.1 (7.0) | 76.6 (6.0) | 77.5 (7.1) |